Study of molecular aggregation in l-tyrosine through superficial tension by Mas Campabadal, Berta
 
  
Study of molecular aggregation in l-tyrosine through superficial tension 
Final Degree Thesis  
UNIVERSITAT POLITÈCNICA DE CATALUNYA 
Escola Superior d’Enginyeries Industrial, Aeroespacial i Audiovisual de Terrassa 
Director: Dr. Manuel José Lis Arias 
Author: Berta Mas Campabadal 
Delivery date: 27th of April of 2020 
Bachelor’s Degree in Chemical Engineering  











First and foremost, I would like to express my gratitude to my thesis director, Dr. Manuel José 
Lis Arias, for his guidance not only during my thesis, but throughout the entire duration of my 
bachelor’s degree. I am truly deeply grateful for having had the privilege of having him not only 
as a teacher and tutor, but as a mentor. 
I would also like to sincerely thank the team at the INTEXTER-UPC Laboratories, for allowing 
me to use their facilities and thus granting me this immense learning opportunity. Especially 
Mercè Simó, who was always helpful when any questions arised and provided a very welcoming 




























L-tyrosine is a proteinogenic amino acid that presents potential as a therapeutic agent, given that 
is a precursor of catecholamines, and thus would be of interest in psychiatric diseases associated 
with low catecholamine synthesis. One of the limits of its free oral administration is its permeation 
through the blood-brain barrier, which is regulated through specific transporter proteins, as well 
as the fluctuating concentrations in plasma levels this type of dosage produces. This study 
presents a possible solution to overcome these challenges through the proposal of a drug delivery 
system able to penetrate said barrier: microencapsulating l-tyrosine. The development of this 
design requires a previous study of the physicochemical characteristics of all the components 
involved in the system, which would enable to find the optimal parameters for encapsulation thus 
also providing the most efficient drug delivery. The study of l-tyrosine’s physicochemical 
properties is carried out through an extensive review of the literature pertaining to it, along with 
a study of its surface tension to analyze its self-assembly and aggregation. The same methodology 
is implemented for the biocompatible surfactant in which the compound will later be entrapped, 
so as to avoid the formation of large aggregates before the execution of its microencapsulation. 
After the determination of said parameters, a few other analytical techniques are suggested for 
further characterization of the complex, alongside an analysis of the best biopolymers to 
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The aim of this study is to propose an optimized drug delivery mechanism for the amino acid l-
tyrosine as an active compound. It will be executed through the interpretation of the surface 
chemistry and self-assembly of said amino acid in aqueous solution as well as entrapped in a 
biocompatible surfactant. This research will facilitate the next step in the drug delivery design 
process: microencapsulation of the active compound, given that it would allow to find the optimal 
concentration of both the active agent and surfactant to be encapsulated. Its application is meant 
for the clinical and biomedical field, specifically for the treatment of clinical symptoms associated 
with low levels of the neurotransmitters dopamine and norepinephrine. 
1.2 Scope 
 
The study was executed through an in-depth investigation into the physicochemical properties of 
l-tyrosine and its current state-of-the-art, the effect of surfactants in formulations, as well as a 
systematic review of the literature relating to surface chemistry of colloidal systems. Specifically, 
research regarding protein-surfactant systems was focused on. Surface tension was measured 




A background knowledge on surface chemistry and the assembly of colloidal systems is required. 
As well as an understanding of the properties, structure, metabolism and biosynthesis of the amino 
acid is necessary to later interpret the evolution of its surface tension. The same principles apply 
in order to study the effect the surfactant of choice has on the assembly of the amino acid. Access 
to a Wilhelmy plate tensiometer is also required in also to execute the experimental design, as 
well as a comprehension of the equations that govern said method.  
 
1.4 Justification of the need 
 
L-tyrosine is a precursor to neurotransmitters and has been proven to be effective in improving 
cognitive function under conditions of adverse stimuli. It has also been proposed for the treatment 
of clinical disorders, specifically those pertaining suboptimal levels of catecholamines, such as: 
depression, Parkinson’s or ADHD. It could even be considered of interest in other disorders such 
as Schizophrenia. The study of its surface tension and self-aggregation would allow to determine 
the optimal concentrations for it to be later microencapsulated, in order to administer a controlled 
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2. Active compound: L-Tyrosine 
 
The active compound studied throughout this project will be the aromatic amino acid tyrosine, as 
a possible drug for therapeutic treatment. Specifically, its levorotatory stereoisomer L-Tyrosine, 
which only appears in mammalian protein [1]. Therefore, only its application and biosynthesis in 
mammals will be considered.   
 
2.1. Chemical structure and properties 
 
Tyrosine is one of the 20 standard proteinogenic amino acids, meaning that it is one of the 
standard genetic code amino acids that are incorporated biosynthetically into proteins during 
translation [2]. Its chemical structure can be seen in Figure 2.1. 
 
 
Figure 2.1. Chemical structure of the amino acid L-Tyrosine. Retrieved from[2]  
Tyrosine (Y) can be considered an uncharged polar and neutral amino acid, as defined through 
the international immunogenetics information system. The standardized criteria used to classify 
the physicochemical properties of the 20 standard amino acids can be seen in Table 2.1[3]. 
 
Table 2.1 The IMGT 'Physicochemical classes of the 20 standard amino acids. Retrieved from [3] 
 
Therefore, tyrosine can be considered a partially hydrophobic amino acid. Even though it has an 
aromatic side chain, its hydrophobic character is tempered somewhat by the presence of an 
uncharged hydroxyl, also granting the amino acid polarity [4].  
 
Hence, it is also the only aromatic amino acid with an ionizable side chain. Its solubility in water 
between the range of pH of 3.2-7.5 and at 25ºC is that of 0,45 g/L [5].  
Study of molecular aggregation in l-tyrosine 
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Figure 2.2. Aromatic amino acids classified in increasing order of hydrophobicity.[6] 
The acid dissociation constants (pKa) of the amino acid are key factors in determining its 
isoelectric point (pI), it being the pH value at which the amino acid has no net charge.  Since 
tyrosine has three functional groups, -amino(-NH3+), -carboxyl(-COOH) and -phenol(-
C6H5OH), it has three dissociation constants.  
 
Figure 2.3. Acid dissociation constants of L-Tyrosine side chains of tyrosine at physiological pH (7,4). Retrieved 
from [7] 
The dissociation constants, the values of which can be seen in Figure 2.3, are the pH values at 
which the functional group in question donate or accept a proton. The isoelectric point is therefore 
calculated as the mean of the pKa values relevant to the form with no net charge, indicated in red 
in Figure 2.4. In the case of tyrosine its value is pI=5,66 [8].  
 
Figure 2.4. Acid-base equilibria for tyrosine. Retrieved from [9] 
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Amino acids with aromatic residues often participate in stacking interactions, which are attractive, 
noncovalent interactions between aromatic rings. They are also referred to as  stacking, given 
they take place when aromatic rings are stacked on top of each other in order to align their  
electron clouds [4].  
 
There are different stacking geometric configurations, the most energetically favorable being the 
T-shaped and parallel. Face-to-face stacking is not energetically favorable due to the repulsion 
forces between the  electron clouds, as can be seen in Figure 2.5 [10]. 
 
 
Figure 2.5. Quadrupolar model of stacking of aromatic rings proposed by Hunter & Sanders (1990). (a) Parallel (b) 
T-shaped and (c) face-to-face configurations.  Retrieved from [10] 
The relatively weak individual interactions combined with the overall stabilizing effects they have 
on the system, allows these types of interactions to provide a flexible framework for different 
biological processes. In fact, this is often taken advantage of during the drug development process, 
specifically in the drug design of pharmaceuticals that exhibit protein-drug binding [11].  
 
These interactions between amino acids are also determining factors in protein-folding processes. 
It is because of this that aromatic amino acids play a decisive role in the structure of a protein. 
The chemical structure of the amino acids interacting also plays a part in the site of the protein it 
is located in.  
 
For instance, Tyr-Tyr stacking interactions mainly take place on the surface of the protein given 
that tyrosine is less hydrophobic than phenylalanine (Phe). However, Phe-Tyr interactions more 
frequently occur at the hydrophobic protein core [12]. 
 
 
Figure 2.6. Minimum energy structures of Phe-Tyr (FY1, FY2, FY3), and Tyr-Tyr (YY1, YY2, YY3, YY4, YY5, 
YY6, YY7, YY8) complexes. Retrieved from [12] 
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2.2. Biosynthesis and metabolism 
 
L-tyrosine is considered a non-essential amino acid given that it is naturally occurring and 
synthesized in vivo through the hydroxylation of the amino acid phenylalanine (phe), in its para 
position [6]. There are two other structural isomers of L-tyrosine, which are synthesized through 
the non-enzymatic free-radical hydroxylation of phenylalanine. These regioisomers are known as 
meta-tyrosine and para-tyrosine [2]. The former has been shown application in the treatment of 
arthritis, as well as neurological disorders such as Parkinson’s and Alzheimer’s [13]. 
 
 
Figure 2.7. The three structural isomers of L-Tyrosine. Retrieved from [2] 
Tyrosine, therefore, can be synthesized in the liver through the hydroxylation of phenylalanine. 
In fact, as much as half of the ingested phenylalanine can be converted to tyrosine in cases where 
a diet may be low on the latter amino acid [14].  
 
Figure 2.8. Conversion of L-phenylalanine to L-tyrosine catalyzed by phenylalanine hydroxylase. Retrieved from 
[14] 
This reaction is catalyzed through the enzyme phenylalanine hydroxylase (PAH), which is 
expressed in the liver and kidney. The overall conversion of phenylalanine to tyrosine can be seen 
in Figure 2.8, the enzymatic mechanism simplified by not considering the nonheme atom the 
coenzyme contains that forms a superoxide. PAH is the rate-limiting factor in the degradation of 
excess phenylalanine in the body, and mutations in its encoding gene can lead to phenylketonuria, 
a severe metabolic disease [14]. In patients with phenylketonuria, tyrosine is therefore considered 
an essential nutrient given that it cannot be converted from phenylalanine [15]. 
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Tyrosine is metabolized into catecholamines, which are physiologically active molecules that can 
act both as neurotransmitters and hormones [16]. Neurotransmitters transfer signals from neuron 
to neuron, while hormones regulate physiological functions. Catecholamines contain a catechol 
group, comprised of a benzene with two adjacent hydroxyl side groups, and an ethylamine side 
chain. Dopamine, norepinephrine (noradrenaline) and epinephrine (adrenaline) are the 
predominant catecholamines found in the brain [17].  
 
 
Figure 2.9. Biosynthetic pathway for catecholamines. Retrieved from [17] 
The biosynthetic pathway of catecholamine production is regulated through the enzyme tyrosine 
hydroxylase, which catalyzes the reaction in a mechanism similar to phenylalanine hydroxylase 
(Figure 2.8) [4]. The hydroxylation of l-tyrosine is considered the rate-limiting step in the 
synthesis of catecholamines.  
 
Once tyrosine has undergone hydroxylation to form DOPA, this substance undergoes 
decarboxylation to obtain dopamine. This conversion takes place in sympathetic and brain 
neurons. Norepinephrine and epinephrine are obtained through further metabolization of 
dopamine, which typically occurs in the adrenal medullary cells and peripheral brain neurons 
[18]. 
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Catecholamine hormones, norepinephrine and epinephrine, cause physiological changes in the 
body in order to activate its ‘fight-or-flight’ response. Increased heart rate and blood pressure due 
to the response of the sympathetic nervous system are some of the effects they produce when 
secreted [16]. However, catecholamines only remain on the bloodstream for several minutes, 
given their short half-life [4].   
 
 
Figure 2.10. Synthesis of melanin through tyrosine. Retrieved from [4] 
Tyrosine is also the precursor of thyroid hormones and the tissue pigment melanin. The synthesis 
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Due to its phenol functionality, the amino acid tyrosine also plays an important role in intracellular 
proteins that partake in signal transduction processes. Tyrosine residues are phosphorylated, 
which activate protein kinases and in turn allow a signal to be propagated through the plasma 
membrane of the cell [19]. A brief description of this process can be seen in Figure 2.11. 
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2.3. Medical interest and potential therapeutic treatment 
 
The rates at which neurotransmitters are synthesized have been shown to be influenced by the 
availability of their precursors in plasma composition [21].  Neutral amino acids, such as tyrosine, 
enter the brain by an uptake through the blood-brain barrier. Tyrosine administration increases 
plasma tyrosine levels, which in turn elevates brain tyrosine levels. Given the appropriate 
conditions, this can therefore stimulate and accelerate the synthesis of catecholamines, 
particularly dopamine and norepinephrine, in the central nervous system and sympathoadrenal 
cells [22]. Thus, it has been suggested that precursor administration would allow to produce 
certain physiological effects by increasing the release of the neurotransmitters [21].    
Tyrosine has been shown to enhance cognitive performance most effectively on individuals 
exposed to stressful situations, that is when there is high cognitive demand. However, it is also 
suggested that genetic predisposition, for instance the genetically determined dopamine function, 
influences its effect as a cognitive enhancer [23].  
Tyrosine administration is most effective under aversive stimuli due to the fact that biosynthesis 
of catecholamines is increased under these conditions, resulting in neurotransmitter levels being 
depleted as well as behavioral depression [18]. The administration of tyrosine would prevent the 
depletion by replenishing the deficit, as well as reversing the stress-induced degradation of 
cognitive function and improving working memory [24]. Therefore, tyrosine supplementation has 
a beneficial effect in situations where neurotransmitter synthesis is stimulated. 
Many cognitive and behavioral studies have been executed to investigate the potential of tyrosine 
as a treatment for clinical symptoms associated with suboptimal catecholamine levels. The 
characteristics and main outcomes of some of them are presented in Table 2.2 [25].  
Table 2.2. Studies reviewed in article [25], along with their characteristics, type and size of samples, potential 
stressors and main outcomes of tyrosine administration. Retrieved from [25] 
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Tyrosine has been proposed for the treatment of depression, as the catecholamine hypothesis of 
affective disorders suggests that this illness may be associated with a decrease in particularly 
norepinephrine and dopamine in the nervous system [26][27][28].   
However, the potential of tyrosine administration as a treatment for psychiatric disorders is 
limited by genetic predisposition, as mentioned previously, as well as the subject’s ability to 
synthesize neurotransmitters.  
In many disorders, catecholamine concentrations are lower than in normal subjects due to an 
impairment in neurotransmitter metabolism, particularly in dopamine and norepinephrine 
synthesis. Therefore, the origin of the disorder is not found in a lack in the necessary precursors 
but rather on the ability to metabolize them. In Parkinson’s disease, for instance, tyrosine 
hydroxylase is less active and therefore tyrosine cannot be converted into l-dopamine at a normal 
rate [25].  
2.3.1. Effect of dosage and routes of administration 
 
There is not yet an agreed upon optimal dosage for tyrosine supplementation. However, doses 
exceeding the daily intake recommended form the World Health Organization, 14mg/kg, would 
presumably be unable to grant additional benefits due to the saturation of the enzyme tyrosine 
hydroxylase [25].  
In the vast majority of human studies, tyrosine supplementation was administered orally. The 
evolution of the plasma levels of tyrosine in time can be seen in the figure below: 
 
Figure 2.12. From top to bottom: plasma tyrosine, tryptophan and neutral amino acids concentrations after a l-
tyrosine oral administration (100mg/kg in black and 150mg/kg in white). Retrieved from [29]. 
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Orally administered tyrosine produces a peak in plasma concentrations approximately two hours 
after consumption, as can be seen in Figure 2.12, and the effects can persist for six to eight hours. 
It also produced a slight decrease of neutral amino acids in plasma concentration, which could be 
attributed to competition between amino acids to cross the blood-brain barrier [29].  
As a proposal for the next stage of the present study, microencapsulation of the drug is discussed 
as an alternative drug delivery system in contrast to the direct administration of the free active 
compound. The entrapment of the active compound in microcapsules would allow for it to be 
released in a controlled manner, in order to avoid peaks of drug concentration as well as possibly 
avoid saturation of the enzymes regulating catecholamine synthesis. It would also provide 
protection and prevent the drug’s degradation, as well as improve its efficacy given that factors 
that difficult its administration could be altered through the materials forming the microcapsule 
[30].  
Further justification on the decision to select this method as the optimal strategy of drug delivery, 
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3. Drug design  
 
The goals of the present study encompass the proposal of an alternative strategy to deliver l-
tyrosine in order to maximize its therapeutic impact. Therefore, different routes of administration 
from the most commonly used to this day are examined, as well as different approaches to enhance 
the amino acid’s physicochemical properties. 
 
3.1. Drug delivery and administration 
 
The ultimate effect of a compound depends on its availability at the site of action once it is 
administered through the appropriate route in an suitable form, therefore its potential therapeutic 
effect is determined through its formulation [31]. Accordingly, formulating a drug delivery 
system able to penetrate the blood-brain barrier, and therefore transport l-tyrosine directly through 
it, could potentially minimize the effect oral administration of tyrosine has on the competition 
between neutral amino acids to cross the blood-brain barrier – further explanation of this 
phenomenon is found in section 3.2.  
 
The direct administration of l-tyrosine could potentially reduce amino acid competition given that 
l-tyrosine transport into the brain would not be regulated through transport proteins, as can be 




Figure 3.1. Schematic view of various pathways of crossing the blood brain barrier. Retrieved from [32] 
As mentioned before, the most common routes of amino acid administration are oral and 
intravenous, in which the amino acid is distributed as a free compound. Through these routes, the 
free amino acid is absorbed from the small intestine, in l-tyrosine specifically by a sodium-
dependent active transport process [33]. Thus, administration of free amino acids is able to 
successfully bypass the digestive system. In fact, the later absorption profile of free amino acids 
is higher than that of the ingestion of whole proteins.   
 
However, plasma amino acid levels of the former administration both peak and decrease more 
rapidly than the latter, which is why administering an amino acid formulation imitating 
physiological absorption kinetics could improve the rate of assimilation into proteins, as well as 
preventing fluctuations of plasma amino acid levels [34].  
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The difference in plasma amino acid concentrations between ingesting a whole protein and 
administering free amino acids can be seen in Figure 3.2. 
 
 
Figure 3.2. Mean change from baseline in total plasma amino acids after feeding whole protein (cottage cheese, ––) 
or an equivalent amount of a free amino acid mixture with identical amino acid composition (---) in fasting healthy 
volunteers (n=10). Retrieved from [34] 
After absorption, amino acids are later metabolized into a variety of different compounds or 
implemented in protein synthesis. In fact, the latter is stimulated both by plasma amino acid levels 
and insulin. When the amino acids are artificially maintained at post-absorptive levels, therefore 
saturating the transporters responsible for their absorption, administration of insulin further 
increases net protein synthesis and decreases protein catabolism [35]. 
 
In contrast, by permeating the blood-brain barrier, namely delivering tyrosine directly to the brain 
could maximize its therapeutic effect given that the amino acid would already be located at the 
major site in which it is employed for catecholamine synthesis, and therefore it could potentially 
minimize the metabolization of the amino acid into other compounds. 
 
However, the specifics regarding the pharmacokinetics and pharmacodynamics involved in the 
transport of pharmaceutical compounds across the blood-brain barrier should be further 
examined, in order asses the optimal parameters of drug design and consequently obtain the 
greatest results after drug administration.  
 
Thus, as the administration of the free amino acid is not able to accomplish such a specific targeted 
delivery directly, the best manner in which to achieve this would  be to develop a specialized drug 
delivery system to enable the release of the drug only once it had permeated the blood-brain 
barrier. Said drug delivery system could also enable a controlled drug release over a prolonged 
period of time, and thus avoid the fluctuations in amino acid concentration as seen through the 
administration of the free amino acid has. 
 
As can be seen in Figure 3.3, there are many strategies available to accomplish this goal.  
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Figure 3.3. Schematic representation of strategies for drug delivery in the brain. Retrieved from [36] 
The strategy considered throughout this study is the non-invasive technique of 
microencapsulating the amino acid in a biocompatible structure, which would confer multiple 
benefits to the active compound, the main ones represented in Figure 3.4.  
 
Figure 3.4. The main biopharmaceutical goals of microencapsulation: material structuration, therapeutic product 
protection and targeted delivery and/or controlled release of the encapsulated biotherapeutics. Retrieved from [30]. 
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Micro and nanoencapsulation offer many advantages in drug delivery, since they are not only able 
to offer a targeted drug delivery at the site of interest, but to also confer many structural benefits 
and protection to the active compound in question. Through microencapsulating tyrosine, 
enzymatic degradation could be prevented, along with an improvement in physical stability and 
increased membrane permeability [30].  
 
Several studies on the nanoencapsulation of tyrosine have already been conducted [37], as well 
as the microencapsulation of compounds involved in l-tyrosine’s metabolic pathway [38] or the 
use of l-tyrosine for the surface functionalization drug carriers [39][40][41][42]. A study has also 
been conducted specifically assessing the antidepressant effect of l-tyrosine loaded nanoparticles 
[26].   
 
However, in this last particular study [26] the influence of the surface chemistry of tyrosine, its 
self-assembly and other physicochemical factors were not considered during its 
nanoencapsulation process. These factors can affect the in vivo performance of a nanoparticle 
formula, as well influence toxic or negative effects of the treatment [43], which incidentally 
highlights the importance of the focus of the present study in the previous assessment of the 
compound’s properties.  
 
The administration of l-tyrosine following this approach could also prove helpful to patients with 
phenylketonuria, which – as mentioned in section 2.2 – is an autosomal recessive disorder caused 
by deficiency of hepatic phenylalanine hydroxylase, making l-tyrosine an essential amino acid 
given it cannot be converted from phenylalanine.  
 
Due to this fact, patients suffering from phenylketonuria have been shown to have reduced levels 
of dopamine. Contributing to these low levels is the fact that high blood phenylalanine levels 
prevent exogenous tyrosine from crossing the blood-brain barrier (BBB). Moreover, 
supplementation with the free amino acid may cause blood tyrosine levels to fluctuate greatly 
during the day in treated patients [13].  The alternative route of drug delivery proposed in this 
study would be able to reduce the fluctuations produced by the administration of the free amino 
acid, given that microencapsulation ensures a controlled release of the compound, making the 
concentrations of the amino acid remain at constant levels, and it would also avoid the competition 
between amino acids to cross the BBB. 
 
This drug delivery system could also be of interest for the treatment of Schizophrenia, given that 
the most common hypothesis for the development of this disease is that tyrosine is less available 
to the brain also due to competition with other amino acids [44]. 
 
Lower and constant doses could also lower l-tyrosine’s potential toxicity. Even though the amino 
acid exhibits very low toxicity, and the studies reporting such toxicity are few [8], abnormally 
high concentrations of tyrosine in the blood have been linked to corneal diseases in rats [45], as 
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Another factor to consider would be the route of administration, which are numerous, as can be 
seen in Figure 3.5. However, not all of them exhibit the same level of bioavailability, which is 
defined as the fraction of drug reaching the systemic circulation [47] and can be expressed as in 
equation (3.1).  
 
 
Figure 3.5. Different routes of drug administration. 
The route of administration of a formulation heavily influences its bioavailability, and therefore 
its effectiveness. The bioavailability of a certain compound can also be heavily dependent on 
various factors, such as: physiological barriers, transporters and the own metabolism of the drug 
before it reaches the targeted site [47].  
 
𝐵𝑖𝑜𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (𝐹) =
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑐𝑖𝑟𝑐𝑢𝑙𝑎𝑡𝑖𝑜𝑛
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In order to ensure the bioavailability of the selected drug delivery mechanism, at least during the 
first stages of the development of the formulation, the preferred route of administration would be 
intravenous administration. The basis of this decision is rooted on the high bioavailability that 
this route presents, as can be seen in Table 3.1., compared to the other alternatives, given that 
through it it’s possible to bypass the major biological barriers that could compromise 
bioavailability.  
 
Table 3.1. Some characteristics of common routes of drug administration. Retrieved from [48] 
 
 
After ensuring the success of the developed drug delivery system, other less invasive, more 
practical and cost-effective routes of administration could be considered, such as: the olfactory 
pathway.  The formulation characteristics, such as volatility, should therefore be re-examined and 
modified in order to guarantee that bioavailability of the drug-delivery system is not hindered by 
external factors.   
 
Figure 3.6. Direct nose-to-brain Access via the olfactory pathway. The therapeutic material injected into the nasal 
cavity diffuses through the olfactory sensory nerves and olfactory glomeruli via passive transport mechanisms. It then 
reaches the brain tissues via projection neurons, tufted of mitral cells. Retrieved from [32] 
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3.2. Microencapsulation as a technique for drug enhancement 
 
Provided that the selected route of administration is an intravenous injection, and this technique 
is classified under the parenteral route of administration, the formulation must be delivered 
through an injectable solution.  
 
All of the factors that alter a drug's ability to cross biologic membranes, its interaction with 
pumping mechanisms, or its metabolism will also affect drug bioavailability, drug effect, and 
drug toxicity [47]. Accordingly, in order to minimize their effect, they need to be inspected and 
taken into consideration.  
 
One of the problems presented when developing a pharmaceutical formulation using tyrosine as 
the active agent is its low solubility, which represents a serious limitation. Hence, its 
bioavailability could be compromised by its efficiency of absorption and transportation to the 
previously defined target tissues. Therefore, the improvement of its properties in formulation is 
essential for its therapeutic potential.  
 
 
Figure 3.7. Approaches for improving drug solubility and bioavailability. 
There are currently various techniques and approaches which are employed to tackle the problem 
of low solubility, as seen in Figure 3.7., in order to prepare an effective and marketable drug. The 
physicochemical properties of the drug and the carrier, as well as their application, are the decisive 
factors when selecting the most appropriate method [49]. The decision to microencapsulate l-
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Microencapsulation would also pose a particularly large advantage compared to other drug 
delivery mechanisms, given that the most commonly involved drug release mechanism is 
diffusion, which is classified as a form of passive transport [50]. The different mechanisms in 
which drugs can be transported through the cellular membrane can be appreciated in Figure 3.8.   
 
 
Figure 3.8. Mechanisms of drug transport through cellular membrane. Retrieved from[48] 
As previously mentioned in section 3.1, amino acid absorption is mediated by active transport, 
specifically through a carrier system, involving the use of transporters in the GI track. The 
transport mechanisms involved in amino acid absorption can be seen in Figure 3.9. In contrast to 
passive diffusion, these carriers often exhibit a concentration beyond which no further increase in 
transport occurs. This is due to the fact that this type of transport can become saturated at high 
substrate concentrations, and therefore presents a disadvantage compared to diffusion 
mechanisms.  
 
These transporters present structural selectivity. Hence, drugs that are structurally similar to the 
transporter’s natural substrates and involve the use of a transporter in its drug delivery 
mechanism, often have to compete with said substrates to bind to the transporters, resulting in 
lower absorption [51]. 
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As previously established and shown in Figure 3.8, drug molecules are be absorbed and 
transported across membranes through several mechanisms, the main ones being: passive 
diffusion (transcellular), passage through pores and junctions (paracellular) and transporter-
mediated (active transport) [48]. 
 
Figure 3.10. Hypothetical example of how Log P can affect oral bioavailability for a compound series. Absorption by 
passive diffusion permeation after oral dosing is generally considered optimal for compounds having a moderate 
LogP and decreases for compounds having higher and lower Log P values. Retrieved from [53] 
The only means for drugs that do not exhibit binding interactions with transporters to be absorbed 
through biological membranes is by passive diffusion. The partition coefficient is the factor that 
directly assesses the ability of a molecule to permeate through membranes. It directly measures 
the ratio of the concentrations of a solute in two immiscible liquids, usually octanol and water, 
when it is in equilibrium across the interface between them [48]. 
 
As can be observed through Figure 3.10, the values at which permeability and solubility present 
optimal bioavailability is very limited. Values out of this short range would present problems with 
one of the two parameters. 
 
L-tyrosine presents a particularly low partition coefficient, with a value of log P= -2.26 [8]. The 
value of this partition coefficient would classify the amino acid’s character as partially 
hydrophilic. Hydrophilicity is defined as the capacity of a molecular entity or substituent to 
interact with polar solvents, in particular with water, or with other polar groups on a molecular 
level [54]. However, hydrophilic substances are not necessarily water soluble, the partition 
coefficient simply determines that a substance interacts more strongly with the polar solvent. Even 
though l-tyrosine presents a partially hydrophilic character, its solubility in water is relatively 
low, as determined in section 2.1. 
 
Compounds with low solubility have a higher difficulty diffusing through membranes, hence their 
permeability is negligible and they consequently present very low bioavailability. In order for a 
drug to diffuse through membranes, it firstly has to be dissolved in the physiological medium. 
The bioavailability of poorly soluble drugs is therefore limited by their solvation rate [55]. 
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Table 3.2 shows the impact that the value of the distribution coefficient, similar to the 
permeation coefficient but considering the pH, can have both on the properties of a drug in vitro 
and in vivo. 
 
Table 3.2. Impact of Log D at physiological pH on Drug-like properties. Retrieved from [53] 
 
The low value of tyrosine’s partition coefficient therefore reflects permeability problems across 
the intestinal track, as well as difficulties in penetrating the blood-brain barrier, as can be 
interpreted through Table 3.2. These problems would only be present if the amino acid were to 
be absorbed through the BBB by a mechanism of diffusion and if administered orally 
 
However, since the absorption of free l-tyrosine both into the brain and small intestine is regulated 
through transporters, it is unable to penetrate the blood-brain barrier without the aid of its structure 
specific carrier proteins. 
 
In order to administer l-tyrosine into the brain through a mechanism of passive diffusion, its 
chemical structure and in turn its partition coefficient would need to be modified to fit the optimal 
values at which permeation of the blood-brain barrier is favorable. Therefore, the value of the 
new partition coefficient at which optimal activity is observed is Log P =2,00 [56], which will be 
achieved in its microencapsulation through the use of excipients. 
 
L-tyrosine’s tendency to form aggregates in solution is also a challenge that must be addressed 
during its development into microcapsules. The tendency of proteins to self-assemble and to form 
aggregations in solution will be extensively analyzed in the following chapters.  
 
In order to confer l-tyrosine the desirable properties to effectively deliver the drug molecules, it 
would be helpful to resort to the use of a biocompatible surfactant, in order to avoid its aggregation 
during the process of microencapsulation. The use of surfactants has long been a primary drug 
delivery strategy to increase the solubility of lipophilic drugs [57], as well as an additive to 
prevent protein aggregation by isolating the protein form interfacial tension [58]. Thus, the role 
of surfactants in drug delivery is essential for the determination of the final microcapsule’s 
characteristics. 
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Therefore, a preliminary study on the surface tension both l-tyrosine’s and the combination of the 
amino acid with the surfactant must be executed, polysorbate 20 being the biocompatible 
surfactant of choice. By studying the properties of tyrosine in solution and its entrapment in a 
biocompatible surfactant, it would be possible to determine the ideal conditions of its 
microencapsulation. 
 
Hence, in order to develop a more sophisticated and effective approach to deliver tyrosine into 
the brain, an analysis on its surface chemistry must be conducted.  
 
It must be noted, that as much as the direct administration of tyrosine to the brain is presented as 
the optimal solution for a number of diseases, the fact that the systems in place for amino-acid 
transport across the BBB have not been fully characterized at a molecular or functional level 
represents a serious limitation for the long-term application of this study. Through the 
combination of molecular research, fibroblast techniques, and brain imaging a new basis for 
clinical research on the role of amino-acid membrane transport could be developed [44]. As 
previously mentioned, a study on the pharmacokinetics and pharmacodynamics involved in the 
transport of pharmaceutical compounds across the blood-brain would also enable to assess the 
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3.3. Outline and current outreach  
 
The present research constitutes the first stage of l-tyrosine’s drug delivery design process, which 
is classified under the preformulation stage of pharmaceutical drug design and comprises the first 
stage in drug development.  
 
The aim of preformulation is to provide knowledge of the physicochemical parameters of the 
drug, establish its physical characteristics and stability, as well as to select the right excipients to 
optimize the drug’s performance while studying their compatibility. Hence, this stage is crucial 
in the early stages of drug development [59], as it is executed as an aid for the later design of an 
optimum drug delivery system [60]. This phase of development requires a multidisciplinary 
approach, as can be seen Figure 3.11, along with its basic outlines [31].  
 
 
Figure 3.11. Outline of preformulation studies. Retrieved from [31] 
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As has been established, l-tyrosine’s main physicochemical properties have been extensively 
characterized and analyzed in previous studies, the literature pertaining to which has already been 
reviewed throughout the previous chapters.  
 
Consequently, from hereon forward, the research focuses on the study of the interactions and the 
stability between the compound and the first excipient: the surfactant. Specifically, the analysis 
on drug-excipient stability will be achieved through the study of its surface chemistry. 
 
Once complete, this study will enable the launch of the second phase: microencapsulation. The 
strategy of the overall drug design process for l-tyrosine proposed in this study can be seen in 
Figure 3.12. 
 
Figure 3.12. Phases involved in drug design in chronological order. 
Therefore, the objective of this study is to develop a foundation to transform l-tyrosine into a 
pharmaceutical formulation that administered in the correct way and in the precise amount, would 
affect the specified target. Whereas during the following phases, the objective will be to provide 
longer stability to the formulation by designing and protecting the compound against 








Study of molecular aggregation in l-tyrosine 
through superficial tension 
 25 
4. Surface and colloid chemistry 
 
Drug carrier shape and size are important factors in drug delivery [61]. The shape of a drug often 
affects the affinity of a drug for carrier molecules or its binding site. Drugs that have a similar 
structure may display competition for their binding sites, as happens between neutral amino acids 
to cross the BBB, and in turn can affect the pharmacokinetics of a drug [47]. Most synthetically 
formulated particles tend to have a spherical geometry, in order to minimize its surface energy. 
Particle size is also a determining factor to consider to when designing particulate systems [61], 
given that smaller molecules tend to be absorbed more easily [47].   
 
Consequently, in order to optimize the drug delivery of tyrosine for its afterward 
microencapsulation, a study of its surface tension was carried out to examine the effect of its 
increasing concentration on its morphology and self-aggregation. Subsequently, another study on 
its superficial tension, alongside the addition of the surfactant polysorbate 20 was also conducted 
to determine the ideal concentration at which it could later be microencapsulated.  
 
In order to interpret the aforementioned phenomenon, a further explanation of the principles of 
surface chemistry, along with a review of a literature pertaining to amino acid self-assembly is 
required.  
 
4.1. Surface tension 
 
Surface tension is the phenomenon resulting from the cohesive forces between liquid molecules. 
On the interior of a homogenous liquid, as can be seen in Figure 4.1, molecules experience 
attracting forces equally in all directions, resulting in a net force value of zero.  
 
However, a molecule located in the surface of the liquid experiences an imbalance of forces due 
to the lack of neighboring molecules. In liquid and air interfaces, molecules on the surface can 
also develop adhesive forces of attraction to those at the other side of the interface. Nonetheless, 
they are far weaker than cohesive forces, which causes an unbalance.  As a result, a net inward 
force is developed and pulls the molecules into the interior of the liquid [62].   
 
Figure 4.1. The molecular interactions of molecules in adjacent phases can be used to visualize the concept of 
surface or interfacial tension. Retrieved from [63]  
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If the surface tension of a liquid is high, it means it is harder to extend the area of said surface and 
more work must be done to distort it, as can be seen in (4.1)[63].  
 
𝑊 = 𝛾 · ∆𝐴 (4.1) 
This work is often referred to as the free energy of the liquid. Hence, the higher the superficial 
tension, the larger is the free energy required to overcome. Excess free energy per unit surface 
area is therefore defined as the surface tension of a liquid, expressed in Nm-1 [62]. It can also be 
measured in dyn/cm, referring to the force in dynes required to deform a surface of 1cm. 
 
In equilibrium, the surface free energy of a system must be at a minimum. Since the geometry of 
a sphere is that of the smallest surface are per unit volume, liquid droplets tend to acquire said 
shape [64]. A higher surface tension also suggests stronger intermolecular forces, therefore 
substances that can form hydrogen or those of higher molecular weight could have greater 
superficial tension [65]. 
 
The distinction between dynamic surface tension and static surface tension also needs to be 
addressed. Static superficial or interfacial tension is the value of the surface tension of a liquid at 
thermodynamic equilibrium. Therefore, this value is independent of time. In contrast, the dynamic 
surface tension is the value of the surface tension at a particular place in time.  
 
In non-homogenous systems, or systems with surface-active agents, the value of this parameter 
is therefore dependent of time and accordingly, can differ from the value at equilibrium. The time 
it takes for a solution with surface-active agents to reach equilibrium is highly dependent on the 
diffusion and adsorption rate of the surfactant. The aforementioned properties are discussed more 
extensively in the following section.  
 
Dynamic surface tension is also of particular interest in processes which involve the rapid 
production of interfaces, given that the kinetics of interface formation are decisive influences in 

















Study of molecular aggregation in l-tyrosine 
through superficial tension 
 27 
4.2. Surfactants and their effect on superficial tension 
 
Surfactants – surface-active agents – are often added in biopharmaceutical applications to offer 
stability and prevent the physical degradation of the protein structure. They are amphiphilic, 
meaning they contain a polar hydrophilic head group and a non-polar hydrophobic tail [67]. 
 
There are several different types of surfactants, their most usual chemical classification seen in 
Table 4.1 is done according to the nature of their polar head group. Nonionic surfactants are 
commonly used as a stabilizing agents in protein formulations in order to prevent degradation. In 
contrast, ionic surfactants are usually used for purposes of pre-treatment of proteins, since that 
they are effective protein denaturants [67]. This is the reason why throughout this study there will 
be a specific focus on the former.  
 
Table 4.1. Classification and characteristics of surfactants. Retrieved from [68] 
 
In aqueous solution, provided their amphipathic nature, surfactants tend to orient themselves so 
that the exposure of their hydrophobic portions are minimized. Thus, they accumulate at the 
interfaces of aqueous and air systems in a way in which only their hydrophilic ends come in 
contact with the water, forming a surface layer. The adsorption process of the surfactant molecules 
to the surface of water causes a reduction surface tension and a decrease of the free energy of the 
system. This is caused by the replacement of high energy water molecules for surfactant 
molecules, given that the interaction between the former molecules is weaker than between two 
water molecules [62].  
 
The hydrophobic force driving surfactants to be adsorbed in the interface can be described by the 
Gibbs energy free equation [69]: 
 
∆𝐺𝑡 = ∆𝐻𝑡 − 𝑇∆𝑆𝑡 (4.2) 
where ΔHt and ΔSt are the enthalpy and entropy of transfer, respectively. 
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The contribution from the entropic term greatly outweighs the enthalpic. However, the former 
experiences a decrease with the addition of surfactant molecules. This phenomenon is thought to 
be the result of the hydrophobic species promoting an ordering of water molecules differently 
from their normal hydrogen-bonded structure of water, organizing themselves around the 
hydrocarbon chain. In order to minimize said effect, the surfactant molecules tend to cluster 
together to reduce the involvement of water molecules, which is enthalpically favored (ΔH<0), 
but entropically unfavorable. The clustering of hydrophobic molecules is known as the 
hydrophobic interaction [70]. 
 
Another important property that must be taken into account when examining surfactants in 
solution is interfacial tension. It is of high importance due to the fact that when suitably altered, 
it can provide a stabilizing influence in various types of dispersions [70]. 
 
The Gibbs adsorption equation shows one of the most fundamental interfacial phenomena caused 
by the addition of surfactants in solution: the decrease of interfacial tension, which is caused 
through the expanding force that surfactant molecules absorbed in the interface provide against 
normal interfacial tension [65]. Through this equation, the relationship between interfacial tension 
and interfacial coverage of the molecules can be derived [63]. It can be expressed through the 
following equation: 
 
𝑑𝛾 = − ∑ Γ𝑖𝑑𝜇𝑖
𝑖
 (4.3) 
Where dγ is the change in surface or interfacial tension of the solvent, Гi the surface excess 
concentration of any component of the system, and μi the change in chemical potential of any 
component of the system [65]. 
 
The surface excess concentration (Г) is defined as the area-related concentration of a surfactant at 
an interface or surface. It is the resulting concentration of the difference between the interfacial 
(Гi) concentration and the concentration at a virtual interface at the interior of the volume phase 
(Гv).  
 
Γ = Γ𝑖 − Γ𝑣 (4.4) 
However, as justified through the hydrophobic effect, surfactants tend to accumulate to in the 
surfaces or interfaces of liquids, thus making the volume excess concentration practically 
negligible. Which is why it is most commonly directly equated with interfacial concentration [71].  
 
The practical application of equation (4.3) is contingent on the theory that the relative adsorption 
of a material at an interface can be determined through experimental data of surface tension as a 
function of bulk solute concentration. In ideal systems, hence isothermal binary systems, where 
the chemical potential is equal to μi ≈ R·T·lnCi, the Gibbs adsorption isotherm can be expressed 
as [72]: 
 









Where Гi is the surface excess of surfactant (mol/cm2), Ci is the solution concentration of the 
surfactant (M), and g may be either surface or interfacial tension (mN/m) [70]. 
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Additionally, the Gibbs absorption isotherm for dilute solutions of a nonionic surfactant can be 
calculated through the following equation [65]: 
 









and the surface concentration can be obtained from the slope of a plot of γ versus log C1 at constant 
temperature (when γ is in dyn/cm (ergs/cm2); R = 8,31·107 ergs/mol /K; Γ1 is in mol/cm2). 
 
Another determining factor of the interfacial characteristics of a solution is the area per molecule 
at the interface. It is, as its name suggests: a measure of the surface area per molecule. Hence, it 
relates to the orientation of the absorbed surfactant molecules, as well as their degree of packing. 








where N is Avogadro’s number and Γ1 is in mol/cm2 [65]. 
 
The comparison between the surface tension and surface excess concentration as a function of 
surfactant concentration can be seen below: 
 
Figure 4.2. Variation of surface excess concentration and surface tension as function of surfactant concentration. 
Retrieved from [73] 
Once the surface excess concentration reaches its maximum value at the critical micellar 
concentration, this parameter remains constant through the increase of surfactant. It is with the 
maximum value of excess surface tension, therefore, that the minimum area per molecule of 
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Furthermore, the performance of a surfactant is also a crucial factor to be evaluated. In order to 
be able to interpret it, its two critical parameters must be observed and evaluated individually, as 
they are not dependent on each other: 
 
- Efficiency. It is the amount of surfactant required to reduce surface tension by a 
significant amount, and can be measured by the negative log of the bulk phase 
concentration necessary to lower surface tension 20 dyn/cm. 
 
- Effectiveness. It is the maximum reduction in tension that can be obtained, regardless of 
the concentration of the surfactant in order to do so. It can be measured by the amount of 
reduction in surface tension has been attained at the critical micelle concentration [65]– 
discussed in the following section. 
 
4.2.1. Critical micelle concentration  
 
Surfactants have the property to form micelles in solution, which is  particularly important given 
it affects a multiple of important interfacial phenomena, as well as the surfactant’s 
physicochemical properties [65].  
 
When the surfactant molecules adsorbed as a monolayer in the interface become so saturated that 
additional molecules cannot be easily distributed, the excess surfactant will begin to agglomerate 
in the bulk of the solution forming micelles. The critical micelle concentration (CMC) is the 
concentration at which this phenomenon occurs. Hence, it is an important parameter for the 
characterization of aggregation. As can be seen in the figure below, once the CMC concentration 
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The physicochemical properties of surfactants, as previously mentioned, are altered once the 
concentration of surfactant in solution reaches the critical micelle concentration, as can be seen 
in Figure 4.4 [70]. 
 
Figure 4.4. Many physical properties exhibit a discontinuity near to the critical micelle concentration (CMC). The 
CMC is not a thermodynamic quantity but is defined by sharp changes in measurable quantities, which occur in a 
concentration range close to the CMC. Retrieved from [75] 
 
Among the properties that exhibit a sudden change in slope is osmotic pressure. Similarly to 
surface tension, after reaching CMC this property has a practical constant trajectory, given that it 
depends on the number of dissolved particles and the interfaces and surfaces are practically 
saturated with surfactant molecules. Electrical conductivity, in the case of ionic surfactants, 
exhibits a sharp decrease since only the counterions of surfactant molecules that are not 
aggregated can carry current.   
 
Overall, the vast majority of physicochemical properties of a given surfactant and solvent system 
will show an abrupt change in slope in a narrow concentration range, which is characterized as 
its critical micelle concentration. Therefore, this suggests that a highly cooperative association 
process between surfactant molecules takes place above this concentration [70].  
 
Resembling the trend surface tension has with increasing concentrations of surfactant past its 
CMC, interfacial tension is also somewhat stabilized –although not to the same degree as surface 
tension – after reaching said point. The stability of both tensions is due to the crowding of 
surfactant molecules at surfaces and interfaces. The comparison between the two tensions can be 
seen in the figure below: 
 
Figure 4.5.  Relationship of Surface tension, interfacial tension, solubilization and CMC with biosurfactant 
concentration. Retrieved from [76] 
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As previously mentioned in section 4.2, critical micelle formation is a parameter that is commonly 
used to measure both the effectiveness and efficiency of a surfactant. Hence, efficient 
biosurfactants exhibit lower CMC values, meaning less concentration of surfactant is necessary 
to decrease surface tension [76]. 
 
The property of surfactants to self-assemble forming micelles has also been taken advantage of 
for the creation of drug delivery systems. Niosomes are vesicle structures derived from the 
spontaneous micellation of nonionic surfactants [77]. They have been researched as a drug 
delivery system able to offer better permeability to otherwise hydrophilic aqueous solutes, by 
entrapping them in the interior of their aqueous compartment, as seen in Figure 4.6 [78].  
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4.2.2. Surfactant of choice: Polysorbate 20 
 
Polysorbate 20 (Tween 20) is commonly used in biopharmaceutical formulations as an excipient, 
in order to obtain a long-term stabilized formulation containing the active compound, enhance its 
solubility and also facilitate drug absorption acting as a vehicle for the active compound [80].  
 
The purpose of this surfactant throughout this study is to optimize the drug delivery of tyrosine, 
by entrapping a determined concentration of the amino acid in surfactant-based micelles, thus 
preventing amino acid aggregates from forming. 
 
Figure 4.7. Chemical structure of polysorbate 20. w+x+y+z refers to the total number of oxyethylene subunits on 
each surfactant molecule and may not exceed 20. Retrieved from [81] 
Polysorbates are nonionic, amphipathic surfactants derived from the esterification of ethoxylated 
sorbitan with fatty acids. Polysorbate 20 in particular is composed of the fatty acid esters of 
polyoxyethylene sorbitan monolaurate, its chemical structure shown in Figure 4.7.  
 
Its hydrophobic nature is provided by the carbohydrate chain, while its hydrophilic character is 
given through the ethylene oxide subunits. The structure in the previous figure represents a 
chemically homogenous polysorbate [69]. 
 
However, most polysorbate solutions sold by manufacturers are generally a heterogeneous 
mixture of the fatty acids seen in Table 4.2. These compositions are defined through the European 
Pharmacopoeia [69]. 
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Since throughout this study the superficial tension of polysorbate 20 in an aqueous solution by 
itself will not be measured, a representation of it retrieved from [82] can be seen in Figure 4.8. 
 
Figure 4.8. Plot of surface tension versus log concentration for polysorbate 20 aqueous solutions. Retrieved from 
[82] 
As can be seen in the figure above, the superficial tension initially decreases linearly with the 
logarithm of the concentration until it reaches its critical micelle concentration at a value of 0.06 
mg/ml. This value can be obtained, as seen in the graph, through the extension of the two lines 
determining the two distinct linear behaviors of the surfactant at different concentrations. 
 
Therefore, the referenced article is able to determine a definite value of the CMC of polysorbate 
20. It can also be observed that extremely low concentrations of surfactant in solution exhibit 
practically the same behavior as that of pure water. Lastly, the linear behavior exhibited in the 
graph suggest the applicability of Gibb’s adsorption isotherm (4.6) to such solutions [82]. 
 
The results of this study suggest that this surface tension method is quick, reliable, and accurate 
for the determination of the CMC of alleged heterodisperse nonionic surfactants [82], thus 
establishing the perfect conditions for the development of the present study.  
 
Additionally, a table summarizing the properties of said surfactant can seen below: 
 
Table 4.3. Chemical properties of Tween 20. Retrieved from [83][80] 
Chemical properties of Polysorbate 20 (Tween 20) 
Chemical formula C58H114O26 
Molas mass 1227.51 [g/mol] 
Density 1.1 [g/mL] 
Boiling point >100ºC 
CMC 60mg/ml 
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4.3. Self-assembly of amino acids  
 
Protein, peptide and amino acid stabilization is one of the most challenging factors in the process 
of biological drug development, their aggregation and self-assembly being one of the most 
common problems encountered throughout all phases of said process [84]. Moreover, the fact that 
that self- assembling systems often play a critical role in physiological functions, has garnered 
them a lot of attention since they present an untapped potential to be applied in biomedical fields, 
as well as nanotechnology [85]. 
 
As can be seen in Figure 4.9, amino acids mostly exist as zwitterions in aqueous solution. This 
unique hydration behavior that amino acids present, although it may not seem very significant for 
solutions of free amino acids in water, it is critical for protein functionality [86]. 
 
 
Figure 4.9. Schematic representation of the equilibrium between the zwitterion form of an amino acid and its cationic 
counterparts. Retrieved from [87] 
In fact, by studying thermodynamic and viscometric properties of amino acids in aqueous solution 
and examining their interactions with the solvent, could in turn improve the understanding of 
biochemical processes such as protein hydration, denaturation and aggregation [86]. 
 
By increasing the concentration of amino acids in aqueous medium, and especially for those that 
exhibit low solubility or are partially hydrophobic, the formation of colloidal aggregates is 
favored. This phenomenon is driven by the inability of molecules to form energetically favorable 
interactions with water [88].  
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The effect that concentration has on protein aggregation, as can be seen in Figure 4.11, is also true 
for other molecules that present surface activity, such as proteins. The aggregation or self-
assembly of this molecules, as seen in the figure below, is usually executed at an interface in order 
to allow said compounds the necessary motion to aggregate between each other [90]. This 
adsorption of the protein or amino acid molecules to the interface can be related to the superficial 
tension of a solution through the Gibbs absorption equation (4.5), therefore the adsorption of a 
protein to the interface thus lowers the interfacial tension, while making its unfolding less likely 
as more protein is adsorbed in the interface.  
 
It must be noted, however, that the application of the Gibbs absorption isotherm is dependent on 
degree of surface hydrophobicity, as well as the physicochemical properties of the protein or 
amino acid. If the hydrophobic character is very pronounced, it may lead to additional processes, 
such as: surface precipitation, the formation of surface sublayers or air-to-liquid surface phase 
transitions. Hence, the adsorption of the protein to the interface cannot be accurately described 
by the Gibbs surface equation [67]. Nonetheless, this is not the case for the present study since as 
previously discussed, l-tyrosine is a partially hydrophobic amino acid. 
 
Figure 4.11. Molecular reorientation of surface-active molecules at the interfaces. (Left) Protein molecules unfold 
less extensively at interfaces as the protein concentration increases. (Right) Orientation of small-molecule surfactants 
is independent of surfactant concentration in the bulk phase Retrieved from [63] 
 
Colloidal aggregaion is the prime source of false positive readout, which as previously mentioned, 
presents a large problem in drug development. The formation of said aggregates is largely driven 
by the chemical structure of the molecule and the medium conditions. It is therefore highly 
dependent on pH value, buffer composition and concentration, as well as the amount and identity 
of surfactant in the buffer [91].  
 
Hence, as the formation of these colloidal systems is highly dependent on the chemical structure 
of the compound, it is also highly dependent on the synergistic effect of various intermolecular 
non-covalent interactions, such as: hydrogen-bonding, π–π stacking, hydrophobic, and van der 
Waals interactions. Therefore, the process of self-assembly is mainly driven by thermodynamics; 
however, another critical factor for structural modulation and integration are the kinetics 
involved[85]. 
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4.3.1. Critical aggregation concentration 
 
The critical aggregation concentration (CAC) is analogous to the critical micelle concentration 
for surfactants. Some compounds, similarly to micelles, when found above their critical 
aggregation concentration nucleation occurs and colloidal aggregates start forming [91], 
regardless of any definite shape or morphology. Likewise, when diluted below the CAC, said 
aggregates will spontaneously disassemble and return to a monomeric state [89]. This references 
the ability of these structures to be reversed, which can also be achieved through the use of a 
surfactant. Further explanation of the reversibility of said systems is explained in section 4.3.2. 
 
Hence, the formation of aggregates must be either reversable or allow its components mobility 
once created. The forces which constitute the bonds formed between the molecules of the 
aggregate must therefore be comparable to the forces that tend to disrupt said aggregate [90].  
 
The particular mechanisms and kinetics on how these aggregates form is still a matter of active 
research, as is the shape they tend to form and their specific morphology [91]. However, as it has 
been discussed in the previous section, since this phenomenon is grounded on the physical 
chemistry of the molecules responsible for aggregation, a prediction on the formation of the 
aggregation could be made through the study of the physicochemical characteristics. 
 
 
Figure 4.12. Poorly water-soluble molecules aggregate at concentrations above the critical aggregation 
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4.3.2. Surfactant-amino acid interactions 
 
Colloidal systems are heavily influenced by the addition of surfactant. In fact, one of their 
defining properties is their detergent reversibility, which is defined as the disruptive effect 
detergents have on colloidal systems, at concentrations greater than the aggregator concentration 
[89].   
 
This could be explained through the effect surfactants have on the increase of solubilization, as 
seen in Figure 4.4, therefore adding surfactant into a protein or amino acid solution would also 
increase their solubility in their aqueous solution.  In fact, this phenomenon can be rationalized 
through the hydrophobic effect. When the hydrophobic portion of nonionic surfactants bind to 
hydrophobic patches of proteins or to a hydrophobic amino acid, thus only its hydrophilic groups 
are exposed to the solvent, it results in a “hydrophobicity reversal”. This effect signifies that the 
protein-surfactant or amino acid-surfactant complex is more hydrophilic than any of them 
individually, which can in turn increase the solubility of the complex [67].   
 
Figure 4.13. Recovery of native rFXIII (A) and formation of soluble (B) and insoluble aggregates (C) as a function 
of Tween 20. Retrieved from [67] 
As can be seen in Figure 4.13, the addition of Tween in factor XIII did not completely block 
protein aggregation, but very effectively prevented the formation of insoluble aggregates. 
aggregates. The addition of surfactants, thus can reduce the propensity of the amino acids  to form 
higher-order aggregates [67].These interactions can also influence the surfactant’s micellization 
process [92], by potentially reducing the concentration at which CMC is achieved, given that the 
ability to form micelles would be promoted by the interaction of surfactants with the presence of 
hydrophobic compounds in solution. The more hydrophobic an amino acid is the larger will be 
the size of water clathrate surrounding its hydrophobic groups, thus increasing molecular 
associations between amino acids and ionic surfactants [86].   
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4.4. Surface tensiometry  
 
Force and optical tensiometry are the most widely accepted methods to measure static surface and 
interfacial tension. In international standards, force tensiometry is the most common method to 
define surface tension. 
4.4.1. Wilhelmy Plate method 
 
 The Wilhelmy Plate is an effective force tensiometry method applied to measure the static 
superficial and interfacial tension. This method yield values of the static surface tension, once the 
system has reached a stage of stable equilibrium [64].   
 
It consists of a thin platinum plate as a probe placed vertically at the surface of the measured 
liquid. The force exerted on it is measured through a very sensitive electronic microbalance 
connected to it [62]. A schematic view of the apparatus used in this method can be seen in Figure 
4.14. 
 
Figure 4.14. Schematic of the apparatus used in the Wilhelmy plate technique. Retrieved from [93] 
Before immersing the plate in the liquid, only its weight is detected, and manually set to zero. It 
is only in the immersion and withdrawal of the plate from the liquid, in a determined depth of 
immersion, that the wetting and buoyancy forces are measured. Buoyancy forces are the upward 
forces exerted by the fluid opposing the weight of the platinum plate [62].  
 
Figure 4.15. Schematic representation of the Wilhelmy plate method. Retrieved from [62] 
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The force exerted (F) on the Wilhelmy plate can therefore be expressed as:  
 
𝐹 =  𝜌𝑝 · 𝐴 · 𝑙 · 𝑔 + 𝑃 · 𝛾 · 𝑐𝑜𝑠𝜃 −  𝜌𝑙 · 𝐴 · ℎ · 𝑔 (4.8) 
P being the perimeter of the plate, γ the static superficial tension, θ the contact angle, p the probe 
liquid density, A the cross-sectional area of the plate, h the immersion depth, l the total length of 
the plate and g the gravitational constant.  
 
Figure 4.16. Schematic force diagram of the plate during immersion. Retrieved from [94] 
The first term in equation (4.8) refers to the weight of the plate, the second is its wetting force 
and the third refers to the buoyance force – expressed as Fh in Figure 4.16. Superficial tension in 
the previous figure is referred to as σ. Both γ and σ are the most common symbols used in the 
literature as a reference to superficial tension. Since the weight of the plate is manually set to zero 
upon introduction on the tensiometer, this term in the force equation can be discarded. 
 
The Wilhelmy method doesn’t offer a direct measurement of the contact angle. However, it is 
very often considered to be negligible, due to the plate being platinum and therefore ensuring its 






The Wilhelmy method is also applicable to dynamic surface measurements by applying it in a 
flowing liquid, with the plate oriented in an inclined direction [95]. The experimental setup of 
which can be seen in the following figure: 
 
Figure 4.17. Inclined plane method of measuring dynamic surface tension. Retrieved from [95] 
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5. Experimental Development 
 
As has been established, the surface tension of increased concentrations of l-tyrosine, as well as 
the surface tension of increased concentrations of Tween 20 with a constant concentration of l-
tyrosine will be measured. Firstly, however, a few parameters need to be taken into consideration, 
such as: pH and solubility. 
 
As mentioned in section 2.1., the solubility of tyrosine is dependent on the pH of the medium in 
which it is dissolved. Figure 5.1 displays the evolution of its solubility function of the pH. 
 
 
Figure 5.1. pH Effect on l-tyrosine solubility at 25ºC. Retrieved from [96] 
In order for the chemical structure of l-tyrosine to have a net charge of zero, and thus be dissolved 
in aqueous solution as a zwitterion, the pH of the solution will need to be close to its isoelectric 
point. Therefore, establishing a range of pH between 5,50 to 6,10 approximately.  
 
Since l-tyrosine is an amino acid, it would be advisable not to interfere unnecessarily with the pH 
values at which it is usually found in protein conformations. In other terms, trying to obtain values 
of higher solubility by submitting the amino acid to pH values at which protein denaturation 
would occur, would be undesirable and thus is discarded.  
 
The solubility of tyrosine at said pH is of 0,45 g/L. Nevertheless, the highest concentration of 
tyrosine in solution will not exceed in any case approximately half of its solubility, so as to fully 
guarantee its complete dissolution in water. 
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5.1. Equipment and material 
 
The surface tensiometer used in this study can be seen in Figure 5.2. As previously mentioned, 
this tensiometer used follows the Wilhelmy plate technique and therefore requires the use of a 
platinum plate, also seen in the figure above.  
 
 
Figure 5.2. A: Tensiometer used for the measurement of superficial tension. B: Wilhelmy plate; C: Register. 
Retrieved from [97] 
The chemical substances manipulated through this study are: L-tyrosine, which was purchased 
from Merk KGaA. Tween® 20 (USP-NF, BP, Ph. Eur.) and Glacial Acetic Acid (Reag. USP, Ph. 
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In order to measure the surface tension, it is obviously required to first develop the solutions of 
which this parameter will be measured. The principles implemented when creating them, along 
with the basic outlines of the methodology can be seen in the following sections.  
 
5.2.1. L-tyrosine solutions 
 
 
Figure 5.3. Schematic representation of the methodology employed in developing l-tyrosine solutions. 
The basic outline of the process implemented when developing the solutions of varying 
concentrations of l-tyrosine can be seen in the figure above. The specific pH of the mother solution 
was obtained through the dilution of acetic acid in distilled water. Through 500mL of this first 
solution, a solution with a concentration of 0,224g/L of l-tyrosine was obtained by dissolving in 
it 0,112g of l-tyrosine. Finally, through the combination of varying volumes of each solution, as 
see in Table 5.1, the final solutions were obtained and thus available for the immediate 
measurement of their surface tension. 
  
Table 5.1. Representation of the concentrations of tyrosine, along with the volumes of mother solution used. 
No. of solution Volume of tyrosine solution [mL] Concentration of L-tyrosine [g/L] 
1 5 0,011 
2 10 0,022 
3 20 0,045 
4 30 0,067 
5 40 0,090 
6 50 0,112 
7 60 0,134 
8 70 0,157 
9 80 0,179 
10 100 0,224 
11 N.A.(1) 0,302 
(1)The last concentration was executed separately, a posteriori of the other solutions, in order to confirm 
the tendency of the measurements observed from the other solutions. 
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The choice to make the volume of the final solutions 100mL was made so that a second lecture 
of surface tension could be executed, in case the first reading of surface tension was somehow 
hindered. Since the tensiometer only required approximately 50mL of solution, its value was 
therefore duplicated. It must also be noted that the solutions were homogenized with the help of 
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5.2.2. L-tyrosine and Tween 20 solutions 
 
 
Figure 5.4. Schematic representation of the methodology employed in developing l-tyrosine and Tween 20 solutions. 
 
As seen in the figure above, the addition of the surfactant in the solution causes a slight deviation 
in the process implemented elaborating the previous solutions. The only major difference in this 
methodology is that the concentration of l-tyrosine is constant, being Tween 20 the factor that 
varies in concentration. Any calculations that are not clearly stated in this document, such as the 
basic calculations involving solution concentrations, can be found in the annexed document. 
 
It must be noted that the value at which tyrosine concentration remains constant was determined 
once the first study of surface tension was executed, along with the interpretation of the resulting 
data. Hence, the explanation behind this decision is justified in section 6.1. It must be  
 
Table 5.2. Representation of the concentrations of tyrosine and tween, along with the volumes of mother solution 















1 49,5 0,5 0,014 0,1112 53,81 
2 49,0 1,0 0,028 0,1112 27,37 
3 48,0 2,0 0,056 0,1112 13,68 
4 46,0 4,0 0,112 0,1112 6,84 
5 42,0 8,0 0,224 0,1112 3,42 
6 40,0 10,0 0,28 0,1112 2,74 
7 36,0 14,0 0,392 0,1112 1,92 
8 30,0 20,0 0,560 0,1112 1,35 
9 10,0 40,0 1,120 0,1112 0,67 
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5.2.3. Measurement of surface tension 
 
As can be seen in the Figure 5.5, the measurement of surface tension followed a specific 




Figure 5.5. Methodology implemented when measuring the surface tension of solutions through the Wilhelmy plate 
technique. 
Firstly, the Wilhelmy plate Wilhelmy platinum plate was cleaned to ensure that no contaminates 
would affect the measurements. A pair of tweezers was used to handle the plate since even oil 
from the hands could contaminate it. It was firstly rinsed with distilled water, and later dipped 
into a nitrating solution in order to eliminate any lingering residues. Lastly, the plate was 
immersed in a heptane solution, which was used to accelerate the drying of the plate, given its 
high volatility. 
 
Once the plate was dry, again while using a pair of tweezers, the tensiometer, in particular its 
microbalance, was calibrated to obtain the most accurate results possible. In some cases, the 
inclusion of an additional weight was necessary in order to contain the scale of the surface tension 
measures within the graphing paper. 
 
After calibration, a first solution containing only distilled water was tested for verification 
purposes. At least three measures of said superficial tension were taken, and the results were 
compared to the reported data in order to confirm their accuracy. For distilled water at room 
temperature (at 25 °C), the surface tension value should be 71,97 dynes/cm [98]. If there was a 
percentage difference greater than 10% between the recorded measurements and reported data, 
the measurements would be considered invalid and therefore would need to be repeated. In some 
cases, the calibration process would also need to be repeated. However, if the percentage 
difference was at or lower than 10%, it would enable to proceed to the next step: the preparation 
and measurements of the other solutions. Needless to say, this step was only executed in the 
beginning of the measurements., meaning it was only carried out when turning on the tensiometer 
at a given lab session.  
 
Once all of the previous steps were completed, the measurement of surface tension of the solutions 
to be analyzed could proceed, following the procedure explained in section 4.4.1. The validation 
of the readings was executed using the same criteria applied for the surface tension of distilled 
water: three or more measurements were recorded and only if the error between them was lower 
or equal to 10% could said measurements be accepted, and thus considered valid. 
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6. Results and calculations 
 
The results corresponding to each measurement in superficial tension are shown below.  
 
6.1. Superficial tension of l-tyrosine 
 
The specific readings obtained through the tensiometer can be observed in Table 6.1 and Table 
6.2. All of them are expressed in [g]. 
 
Table 6.1. Direct measurements extracted from the tensiometer of solutions 1-5 of varying l-tyrosine concentrations. 
Nº of Solution 1 2 3 4 5 
1st Measurement 294,0 285,0 295,0 291,0 290,0 
2nd Measurement 293,0 287,0 295,0 291,0 290,0 
3rd Measurement 292,0 288,0 295,0 291,0 290,0 
Average 293,0 286,7 295,0 291,0 290,0 
 
Table 6.2. Direct measurements extracted from the tensiometer of solutions 6-11 of varying l-tyrosine 
concentrations. 
Nº of Solution 6 7 8 9 10 11 
1st Measurement 297,0 290,0 300,0 286,0 279,0 269,0 
2nd Measurement 296,0 290,0 300,0 285,0 278,0 265,0 
3rd Measurement 295,0 290,0 300,0 284,0 277,0 264,0 
Average 296,0 290,0 300,0 285,0 278,0 266,0 
 
The following figures show the resulting superficial tensions obtained in relation to the tyrosine 
concentration. 
 















The force measured is divided by four given it is the value of the perimeter of the plate which 
comes in contact with the solution. Since the units at which the force has been measured are gram-
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Table 6.3. Results of the superficial tension measurements of increasing concentrations of L-Tyrosine. 
Nº of Solution Superficial Tension [dyn/cm] Concentration [g/L] 
1 71887,6 0,011 
2 70333,7 0,022 
3 72378,3 0,045 
4 71396,9 0,067 
5 71151,5 0,090 
6 72623,6 0,112 
7 71151,5 0,134 
8 73605,0 0,157 
9 69924,8 0,179 
10 68207,3 0,224 
11 65263,1 0,302 
 
As mentioned in section 4.2.2, through the study of surface tension of polysorbate 20, the critical 
aggregation concentration of l-tyrosine can be obtained by equating the two linear behaviors 
exhibited by the amino acid in the figures below 
 
Figure 6.1. Superficial tension function of L-tyrosine concentration. 







Therefore, as can be through Figure 6.1, the surface tension of l-tyrosine in aqueous solution 
experiences a pronounced decrease in the concentration 0,152g/L. This could be attributed to the 
fact that from this concentration, l-tyrosine begins to assemble forming aggregates, thus 
decreasing the superficial tension of the solution, as predicted in section 4.3.  
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Before this phenomenon starts to happen, it is suggested that tyrosine is in isolated molecules, 
only after the critical aggregation concentration does it start to form aggregates. 
 
 
Figure 6.2. Superficial tension function of log(L-Tyrosine) concentration 
Figure 6.2 shows the completely linearized behavior of the increase of concentration of l-tyrosine. 
Through this figure, the point at which tyrosine aggregation starts to occur can be seen clearly by 
the abrupt change of slope the graph exhibits past LogC=-0,8.  
 
Having said this, the optimal concentration for l-tyrosine for later encapsulation would be at any 
value before the sudden decrease in superficial tension, given that passed this point l-tyrosine 
tends to agglomerate and its microencapsulation would result in larger particles. The chosen 
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6.2. Superficial tension of l-tyrosine in increasing surfactant concentrations 
 
The specific readings obtained through the tensiometer can be observed in Table 6.4 and Table 
6.5. All of them are expressed in [g]. 
 
Table 6.4. Direct measurements extracted from the tensiometer of solutions 1-5 of varying tween 20 concentrations. 
Nº of Solution 1 2 3 4 5 
1st Measurement 191,0 171,0 151,0 157,0 153,0 
2nd Measurement 189,0 170,0 150,5 156,0 151,0 
3rd Measurement 188,0 170,0 150,0 155,0 150,0 
Average 189,3 170,3 150,5 156,0 151,3 
 
Table 6.5. Direct measurements extracted from the tensiometer of solutions 6-11 of varying tween 20 concentrations. 
Nº of Solution 6 7 8 9 10 
1st Measurement 152,0 152,0 150,0 150,0 149,0 
2nd Measurement 150,0 152,0 150,0 149,0 149,0 
3rd Measurement 149,0 151,0 150,0 149,0 149,0 
Average 150,3 151,7 150,0 149,3 149,0 












0(1) 72623,6 N.A. (1) 0,112 N.A. (1) 
1 46452,9 0,014 0,1112 53,81 
2 41791,3 0,028 0,1112 27,37 
3 36925,2 0,056 0,1112 13,68 
4 38274,6 0,112 0,1112 6,84 
5 37129,6 0,224 0,1112 3,42 
6 36884,3 0,280 0,1112 2,74 
7 37211,4 0,392 0,1112 1,92 
8 36802,5 0,560 0,1112 1,35 
9 36638,9 1,120 0,1112 0,67 
10 36557,2 1,400 0,1112 0,54 
(1) Data point from the surface tension study of l-tyrosine, added in order to contrast the superficial tension 
results.  
 
The superficial tension for the solution for the mixture of tyrosine and the surfactant, shown in 
Figure 6.3, illustrates that even in the solution where there is the least concentration of surfactant, 
the superficial tension is significantly lower than for any of the tyrosine/water solutions (Figure 
6.1Error! Reference source not found. ).  
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Figure 6.3. Superficial tension function of Tween 20 concentration, while maintaining a constant concentration of 
0,112g/L of l-tyrosine. 
Moreover, there is a further decrease in superficial tension with an even more prominent slope 
than in the previous graph, signifying that increasing concentrations of surfactant decrease 
superficial tension more rapidly than those of l-tyrosine alone. 
 
Therefore, applying the same method as done for the previous values of surface tension, critical 
micelle concentration can be found by equating the two linear behaviors that the surfactant 
exhibits. 
 







Therefore, the critical micelle concentration for the system of l-tyrosine and Tween 20 is at a 
concentration of the latter of 0,046g/L.  
 
This value of critical micelle concentration is lower in comparison to the value of critical 
concentration of the surfactant on its own in aqueous solution, as seen in section 4.2.2, which was 
determined to be 0,06mg/m (0,06g/L).Therefore, as rationalized in section 4.3.2, the l-tyrosine 
and Tween 20 complex exhibits an increase of solubility compared to the compounds on their 
own, which is attributed to the previously discussed “hydrophobicity reversal”. 
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Figure 6.4. Superficial tension function of log of Tween 20 concentration, while maintaining a constant 
concentration of 0,112g/L of l-tyrosine. 
Once again, Figure 6.4, shows the completely linearized behavior of the complex with the 
increase of concentration of Tween 20. Through this graph, and the equating of the two linear 
behaviors exhibited, the critical micelle concentration would be achieved at a concentration of 
0,051g/L, which still confirms the effect the surfactant has on the amino acid and the implications 
the complex has on the CMC. 
 
In conclusion, a value above the critical micellar concentration would be considered as a good 
option for the later microencapsulation of l-tyrosine. However, it is recommended the 
concentration of an excipient be limited to the minimal amount in a formulation [67], therefore 
amounts slightly above the critical micellar concentration determined by this study would be 
considered optimal. 
 
The later step in this analysis would be to execute a particle size analysis on of the micelles created 
through this method, in order to determine the optimal concentration of surfactant to add so that 
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6.3. Surface excess concentration and minimum area per molecule 
 
As discussed in section 4.2, the Gibbs absorption equation can be applied to relate measurements 
of surface tension to the concentration of absorbed species at the air-liquid interface, only for 
binary systems. Therefore, an approximation of the excess surface evolution for the various 
readings of surface tension relating to the increasing concentration of l-tyrosine has been 
executed. The data for the surface excess concentrations of the solutions were estimated from 
Gibbs adsorption equation (4.5), and can be seen in the  figure below: 
 
Figure 6.5. Influence of the tyrosine concentration on the excess surface concentration. 
The calculations were made considering R = 8,31·107 ergs/mol /K and an ambient temperature of 
25ºC (298K). 
 
As can be seen in Figure 6.5Error! Reference source not found. , the values of the excess 
surface concentration, once having reached the critical aggregation concentration remain 
practically constant. The reason behind this phenomenon might be attributed once again to the 
formation of aggregates in solution, and once having reached the critical aggregation 
concentration at which the excess surface concentration is maximal (4,21·10-7 mol/cm2), the 
surface becomes saturated. 
 







(6,022 · 1016) · (4,21 · 10−7)
= 3,9 · 10−2 𝑐𝑚2𝑝𝑒𝑟 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒 
 
The Gibbs adsorption equation cannot be applied for the values of surface tension regarding the 
complex of l-tyrosine and Tween 20, due to it not being a binary system, hence it would exhibit 
a more complex behavior. However, the maximum surface excess concentration of Tween 20, 
and its area per molecule have been determined through the previously cited study [82], the values 
of which are 3,44·10-10 mol/cm2  and a value of 4,84·10-14 cm2 per molecule.  
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7. Planning and programming of the next stage 
 
Drug delivery encompasses the approach, formulation, technology and system involved in 
transporting drugs into the body. It ensures that the drug is presented in the correct form in which 
it will be administered, along with the release from its dosage form, adsorption and transportation 
to the targeted site. The evaluation and development of all of these properties would be 
implemented during the next stage of this study, which constitutes the design of the drug 
prototype. The different phases that constitute this process are illustrated in Figure 7.1.  
 
 
Figure 7.1. Phases of prototype development. Retrieved from[59] 
The importance of the preformulation stage developed throughout this project can be seen in 
Figure 7.2, as the results obtained through this first stage have an influence in a great number of 
departments in charge of the prototype development process. 
 
Figure 7.2. Different groups in a drug's discovery and development stages. Retrieved from [59] 
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7.1. Additional preformulation strategies 
 
Another study on the surface tension of l-tyrosine could be conducted, only this time substituting 
the nonionic surfactant for an anionic, given anionic surfactants exhibit a higher solubilizing 
power than nonionic surfactants [65]. An additional one could be carried out using different 
concentrations of both, as often low concentrations of anionic surfactants are used alongside 
nonionic for stabilization purposes. Later, a particle size analysis of the resulting particles of all 





An in-depth study into the physicochemical characteristics into the biopolymers of choice would 
be necessary. The recommended biopolymers would be gum Arabic and chitosan, the main 
physicochemical characteristics and applications of which can be seen in the table below.  
 
Table 7.1.  Examples of polysaccharides of various origin used in microencapsulation. Retrieved from [99] 
 
Chitosan has been extensively used in microencapsulation drug delivery system given that it is 
characterized by its high biocompatibility and also presents antibacterial qualities that might 
prove helpful to the formulation, in order to avoid infections[100][101].  
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There are a several studies that have employed these polysaccharides as their biopolymers of 
choice, the guidelines of which can be  implemented in future projects as in order to have baseline 
of development [102][103][104].  
The method employed in these studies is complex coacervation, although there are other methods 
of microencapsulation, as seen in the figure below. An assessment of the optimal technique could 
be executed in order to determine the best microencapsulation technique specifically for tyrosine.  
 
Table 7.2. Different microencapsulation techniques. Retrieved from [105] 
 
 
The formation of microcapsules could be executed by combining different weights and relation 
of biopolymer concentration, so that with their later characterization the optimal polymer ratio 
could be determined. The characterization of the resulting microcapsules could be conducted 
through a series of analytical techniques once these were developed. Among the most commonly 
used techniques are zeta potential, thermogravimetric analysis, an assessment of their morphology 
through scanning electron microscopy and encapsulation yield Lastly, a study on the different 
mechanism of the compound’s drug release would be required, as there are multiple ways in 
which the core materials can be delivered through the microcapsules. The stimulus that would 
cause the release of the active agent should be considered. 
 
 





Study of molecular aggregation in l-tyrosine 
through superficial tension 
 57 
 
7.3. Gannt Diagram 
 
The following Gannt diagram illustrates the planification of the next stages: 
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8. Budget summary 
 
All of the reagents, materials and equipment used throughout this study has been supplied by the 
UPC-INTEXTER Laboratory. Therefore, the calculation of the budget is an approximation of the 
resulting cost of development of said study, in the case of not having had access to any of the 
supplied resources. 
Table 8.1. Global budget 
Concept Cost 
Reagents 429,53 
Equipment and material 384,77€ 
Working hours 4.800,00€ 
Total 5.614,3€ 
 
It is worth noting that the cost regarding the hours of work has been calculated through 
multiplying the workload related to this project (24 ECTS = 600h) by 8€/h, as it is the 
recommended hourly compensation for undergraduate students, as advised by UPC [107]. A more 
detailed explanation and calculation of the cost of the reagents, materials and equipment can be 
found in the document regarding the whole budget.  
9. Environmental implications 
 
The development of this project involved the handling and utilization of several chemical 
substances, the environmental impact of which is not assessed given that their respective chemical 
residues were all disposed of following the protocol established by the general guidelines  
specified by the Spanish Ministry of Labor and Social Affairs along with the National Institute of 
Workplace Safety and Hygiene [108].  
 
It must be specified that most of the quantities of the reagents used were so insignificant and 
diluted in distilled water that they qualified to be poured directly down the drain. The only 
exception were the quantities of pure acetic acid used (5-10mL) to make the first solutions, which 
were disposed of in the jugs pertaining to organic acid waste in order to minimize its 
environmental impact. 
 
In addition, the use of the articles used such as gloves, Pasteur pipettes and pipette tips, among 
other items has strictly been limited to only when absolutely essential, and the collection of the 
waste of such objects was always disposed of at the waste container identified as “contaminated 
plastic”. The specific containers referenced were later managed and ultimately disposed of by an 








Study of molecular aggregation in l-tyrosine 
through superficial tension 
 59 
The carbon footprint that the development of this project has is very minimal. The only parameters 
that can be taken into account and quantified are the indirect ones, pertaining to the electric 
consumption of equipment such as the tensiometer, magnetic stirrer and even the computer. The 
direct parameters, such as vehicle transport, are not applicable since they cannot be verified and 
directly quantified.  
 
Therefore, the table below offers a brief approximation of the impact of the electric consumption 
that the use of the equipment has, using as a guideline the documentation generated by the Spanish 
Office for Climate Change [109]. 
 
Table 9.1. Assessment of the environmental impact of the study. 





[kg of CO2/kWh] 
[110] 
Carbon footprint [kg 
of CO2] 
Magnetic stirrer 10 0,090[111] 0,37 0,33 
Microbalance 1 0,003 [112] 0,37 0,00 
Tensiometer 10 0,040 [113] 0,37 0,15 
Computer 300 0,065 [114]1  0,37 7,22 
Total 7,70 
1At maximum capacity 
 
It must be noted that it is an estimate of the time of usage of the resources employed throughout 
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The preformulation stages within the development of a drug delivery system are crucial to the 
process of drug design. It is through this stage that the physicochemical properties of a compound 
are investigated and therefore characterized, so that in the later stage of prototype development 
through various methods of chemical manipulation they can be optimized to fit the specific needs 
of the target in question. 
 
After an in-depth analysis of the challenges surrounding the free delivery of the amino acid as a 
therapeutic agent, involving not only l-tyrosine’s physicochemical properties and self-assembly, 
but also considering the characteristics of the blood-brain barrier and the agents regulating its 
transport, microencapsulating the compound was concluded to be the most effective option as a 
drug delivery system.  
 
In order to develop said system, as previously mentioned, a preformulation study of all of the 
components involved was essential so as to determine the optimal parameters for its 
microencapsulation specifically. Since the l-tyrosine is one of the 20 standard proteogenic amino 
acids, its physicochemical properties had already been extensively characterized and analyzed in 
previous studies, hence an in-depth review was conducted of the pertaining literature to enable 
the interpretation of the study on its superficial tension. The same methodology was implemented 
for the study of the surfactant, along with the study of its effect on intermolecular forces and 
interactions with amino acids.  
 
Finally, a successful interpretation was derived from the study of the surface tension of the amino 
acid l-tyrosine, along with the addition of a surfactant. Hence, it was determined that the optimal 
concentration at which to microencapsulate the amino acid in order to avoid its aggregation was 
at 0,112g/L. Through the study of the complex comprised of l-tyrosine and the surfactant, the 
optimal range of concentration of latter was able to be determined. 
 
Through the realization of this study it would now be possible to execute the next stage of drug 
development: the actual microencapsulation process and assessment of its drug delivery. 
However, it must be considered that although the direct administration of tyrosine to the brain is 
presented as the optimal solution for a number of diseases, further research on the molecular, 
pharmacokinetic and pharmacodynamic properties of amino acid transport across the blood-brain 
barrier would have to be conducted. This would enable the assessment of the optimal parameters 
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